GLUCOCORTICOIDS AND ARTERIAL HYPERTENSION IN INTERNAL ORGANS RECIPIENTS
Abstract
In this paper we present a review of literary data about the modem views on glucocorticoid arterial hypertension arrangement in donor organs recipients. Arterial hypertension is one of the main risk, pacing for cardiovascular complications development. In cases with glucocorticoids uptake arterial blood pressure develops approximately in 15–20%. We generalized the main schemes participating in genesis of the arterial hypertension induced by glucocorticoids: a time delay of sodium and increase in circulating liquid volume, GC-dependent vasoconstriction, increased synthesis of catecholamines and beta-1 adrenergic receptor expression, change of noradrenaline sensitivity as a result of the increased endothelin synthesis. In a practical manipulation it is necessary to use non-steroid protocols or minimize doses in internal organs recipients, weighing risks of transplant rejection and possible undesirable side responses in cases with glucocorticoids administration.
About the Authors
E. D. Kosmacheva
Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1, The Krasnodar Krai Ministry of Health; Kuban State Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
S. M. Martirosyan
Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1, The Krasnodar Krai Ministry of Health; Kuban State Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
N. A. Zubareva
Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1, The Krasnodar Krai Ministry of Health; Kuban State Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. E. Babich
Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1, The Krasnodar Krai Ministry of Health; Kuban State Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Литвинова Л.С. Геномные и негеномные эффекты глюкокортикоидов. Гены и клетки. 2017; 1(12): 27-33
2. Cruz-Topete D., Cidlowski J.A. One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. Ncuroimmunomodulation. 2015; 22(1-2): 20-32.
3. Baschant U., Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. Journal of Steroid Biochemistry & Molecular Biology. 2010; 120(2-3): 69-75.
4. Калинина T.C., Сухарева E.B., Дыгало H.H. Канонический и неканонический механизмы действия глюкокортикоидных гормонов стресса. Успехи физиологических наук. 2016; 3(47): 59-69.
5. Revollo J.R., Cidlowski J.A. Mechanisms generating diversity in glucocorticoid receptor signaling. Glucocorticoids and Mood: Ann. N.Y. Acad. Sсi. 2009; 1179: 167-78.
6. Kelly A., Bowen H., Jee Y.K. et al. The glucocorticoid receptor beta isoform can mediate transcriptional repression by recruiting histone deacetylases. J. Allergy Clin. Immunol. 2008; 121(1): 203-8.
7. John K., Marino J.S., Sanchez E.R., et al. The glucocorticoid receptor: cause of or cure for obesity? Am. J. Physiol. Endocrinol. Metab. 2016; 310(4): 249-57.
8. Oppong Е., Cato A.B. Effects of Glucocorticoids in the Immune System. In: Wang J.C., Harris Ch., editors. Glucocorticoid signaling from molecules to mice to man. Advances in Experimental Medicine and Biology. New York: Springer; 2015: 217-33.
9. Adcock I.M., Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunology and Cell Biology. 2001; 79(4): 376-84.
10. Saleh K.J., Kurdi A.J., El-Othmani M.M. et al. Perioperative Treatment of Patients with Rheumatoid Arthritis. J. Am. Acad. Orthop. Surg. 2015; 23(9): 38-48.
11. Hartmann K., Koenen M., Schauer S. et al. Molecular Actions of Glucocorticoids in Cartilage and Bone During Health, Disease, and Steroid Therapy. Physiol. Rev. 2016; 96(2): 409-417.
12. Peppa M., Krania M., Raptis S.A. Hypertension and other morbidities with Cushing’s syndrome associated with corticosteroids: a review. Integr Blood Press Control. 2011; 4: 7-16. DOI: 10.2147/IBPC.S9486. Epub 2011 Mar 3.
13. Ayroldi E., Macchiarulo A., Riccardi C. Targeting glucocorticoid side effects: selective glucocorticoid receptor modulator or glucocorticoid-induced leucine zipper? A perspective. Faseb J. 2014; 28(12): 5055-70.
14. Souverein PC, Berard A, Van Staa TP et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004; 90(8): 859-65. DOI: http://dx.doi.org/10.1136%2Fhrt.2003.020180.
15. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis. 1999; 33(5): 829-839.
16. Bоhlke M., Barcellos F.C., Rocha M., et al: Predictors of hypertension following successful renal transplantation: a population-based study. Transplant Proc. 2009; 41: 3743-46.
17. Nakamoto H., Suzuki H., Kageyama Y., et al. Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs. Clin Exp Hypertens A. 1991; 13(4): 587-606. DOI: http://dx.doi.оrg/10.3109%2F10641969109045071
18. Gardiner S.M., Kemp P.A., March J.E., et al. Effects of dexamethasone and SB 209670 on the regional haemodynamic responses to lipopolysaccharide in conscious rats. Br J Pharmacol. 1996; 118(1): 141-9. DOI: http://dx.doi.org/10.111 l%2Fj.14765381.1996.tbl5377.x.
19. Pirpiris M., Sudhir K., Yeung S., et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension. 1992; 19(6Ptl): 567-74. DOI: http://dx.doi.org/10.1161%2F01.HYP.19.6.567
20. Munoz SJ. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis, and management. Liver Transpl. Surg. 1995; 1(5): 29-38.
21. Pagadala M., Dasarathy S., Eghtesad B., McCullough A.J. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl. 2009; 15(12) 1662-1670.
22. Hryniewiecka E., Zegarska J., Paczek L. Arterial hypertension in liver transplant recipients. Transplant. Proc. 2011; 43(8): 3029-3034.
23. Claes K., Meier-Kriesche H.U., Schold J.D. et al. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study // Nephrol. Dial. Transplant. 2012; 27(2): 850-857.
24. Miller L.W. Cardiovascular toxicities of immunosuppressive agents // Am. J. Transplant. 2002; 2(9): 807-818.
25. Rike A.H., Mogilishetty G., Alloway R.R. et al. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin. Transplant. 2008; 22(2): 229-23 5.
26. Карабаева А.Ж. Минералкортикоидные рецепторы и альдостерон. Вестник Витебского государственного медицинского университета. 2008; 2(7): 11-16.
27. Есаян A.M., Каюков И.Г., Караваева А.Ж. Минералкортикоидные рецепторы: структура, механизмы активации. Нефрология. 2006; 2(10): 28-32
28. Ferrari R. Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease. Best Pract Res Clin Endocrinol Metab. 2003; 17: 575-589.
29. Kassel LE, Odum LE. Our own worst enemy: pharmacologic mechanisms of hypertension. Adv Chronic Kidney Dis. 2015; 22: 245-52. doi: 10.1053/j.ackd.2014.10.002.
30. State registry of medicines. [Государственный реестр лекарственных средств (In Russ.)] http://grls.rosminzdrav.ru.
31. Hari P., Bagga A., Mantan M. Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr. 2004; 41: 993-1000.
32. Clyburn E.B., Di Pette D.J. Hypertension induced by drugs and other substances. Semin Nephrol. 1995; 15: 72-86.
33. Hricik D.E., Lautman J., Bartucci M.R., et al. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation. 1992; 53(6): 1232-1235.
34. Taler S.J., Text S.C., Canzanello V.J., et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation. 1996; 62(11): 1588-1592.
35. Saruta T., Suzuki H., Handa M., et al. Multiple factors contribute to the pathogenesis of hypertension in Cushing’s syndrome. J Clin Endocrinol Metab. 1986; 62(2): 275-9. DOI: http://dx.doi.org/10.1210%2Fjcem-62-2-275.
36. Magiakou M.A., Smyrnaki P., Chrousos G.P. Hypertension in Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab. 2006; 20(3): 467-82. DOI: http://dx.doi.org/10.1016%2Fj.beem.2006.07.006.
37. Kirilov G., Tomova A., Dakovska L. et al. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing’s syndrome. Eur J Endocrinol. 2003; 149(6): 549-53. DOI: http://dx.doi.org/10.1530%2Feje.0.1490549.
38. Sakaue M., Hoffman B.B. Glucocorticoids induce transcription and expression of the alpha IB adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest. 1991 ; 88(2): 385-9. DOI: http://dx.doi.org/10.1172%2FJCI115315.
39. Haigh R.M., Jones C.T. Effect of glucocorticoids on alpha 1-adrenergic receptor binding in rat vascular smooth muscle. J Mol Endocrinol. 1990; 5(1): 41 -8.
40. Yard A.C., Kadowitz P.J. Studies on the mechanism of hydrocortisone potentiation of vasoconstrictor responses to epinephrine in the anesthetized animal. Eur. J. Pharmacol. 1972; 20: 1-9.
Review
For citations:
Kosmacheva E.D., Martirosyan S.M., Zubareva N.A., Babich A.E. GLUCOCORTICOIDS AND ARTERIAL HYPERTENSION IN INTERNAL ORGANS RECIPIENTS. Innovative Medicine of Kuban. 2017;8(4):60-64. (In Russ.)
Views:
2205
Email this article 
